CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy
Authors
Keywords
Endoxifen, CYP3A4, Vitamin D, CYP2D6, Tamoxifen efficacy, Therapeutic threshold
Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume 139, Issue 1, Pages 95-105
Publisher
Springer Nature
Online
2013-04-11
DOI
10.1007/s10549-013-2511-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts
- (2013) Inna Y. Gong et al. BREAST CANCER RESEARCH AND TREATMENT
- Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation
- (2012) Ranjit K. Thirumaran et al. BIOCHEMICAL PHARMACOLOGY
- CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8
- (2012) M. P. Goetz et al. CLINICAL CANCER RESEARCH
- Effects of CYP Induction by Rifampicin on Tamoxifen Exposure
- (2012) L Binkhorst et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
- (2012) James M. Rae et al. JNCI-Journal of the National Cancer Institute
- CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
- (2012) Meredith M. Regan et al. JNCI-Journal of the National Cancer Institute
- Tamoxifen and CYP2D6: A Contradiction of Data
- (2012) D. L. Hertz et al. ONCOLOGIST
- Ultraviolet Sunlight Exposure During Adolescence and Adulthood and Breast Cancer Risk: A Population-based Case-Control Study Among Ontario Women
- (2011) L. N. Anderson et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma
- (2011) T E Mürdter et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes
- (2011) L Madlensky et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Dextromethorphan As a Phenotyping Test to Predict Endoxifen Exposure in Patients on Tamoxifen Treatment
- (2011) Anne-Joy M. de Graan et al. JOURNAL OF CLINICAL ONCOLOGY
- Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study
- (2011) William J. Irvin et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacogenetics of Endocrine Therapy for Breast Cancer
- (2010) Michaela J. Higgins et al. Annual Review of Medicine
- 4β-hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans
- (2010) Ulf Diczfalusy et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Endoxifen, the Active Metabolite of Tamoxifen, Is a Substrate of the Efflux Transporter P-Glycoprotein (Multidrug Resistance 1)
- (2010) W. A. Teft et al. DRUG METABOLISM AND DISPOSITION
- Association of serum 25-hydroxyvitamin D with the risk of death in a general older population in Finland
- (2010) Jyrki K. Virtanen et al. EUROPEAN JOURNAL OF NUTRITION
- Significant Effect of Polymorphisms inCYP2D6andABCC2on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients
- (2010) Kazuma Kiyotani et al. JOURNAL OF CLINICAL ONCOLOGY
- Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs
- (2010) D Wang et al. PHARMACOGENOMICS JOURNAL
- The Tamoxifen Metabolite, Endoxifen, Is a Potent Antiestrogen that Targets Estrogen Receptor for Degradation in Breast Cancer Cells
- (2009) X. Wu et al. CANCER RESEARCH
- Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen
- (2009) Werner Schroth JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Up-Regulation of Transporters and Enzymes by the Vitamin D Receptor Ligands, 1 ,25-Dihydroxyvitamin D3 and Vitamin D Analogs, in the Caco-2 Cell Monolayer
- (2009) J. Fan et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test
- (2009) Beatrice Oneda et al. Pharmacogenetics and Genomics
- Drug Interactions and Pharmacogenomics in the Treatment of Breast Cancer and Depression
- (2008) N. Lynn Henry et al. AMERICAN JOURNAL OF PSYCHIATRY
- Addressing the health benefits and risks, involving vitamin D or skin cancer, of increased sun exposure
- (2008) J. Moan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started